GlassScriptPhysician profile
Scott D Legunn
NPI 1609193184
$2,378.70
in general payments reported to CMS, 2019-2025
28 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.76 · 2023: $357 · 2024: $903 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,232 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.30 |
| Education | $131.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $546.70 | 2022-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $419.81 | 2023-2025 | |
| Janssen Biotech, INC. | $323.55 | 2023-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $189.97 | 2023-2025 | |
| Ucb, INC. | $131.40 | 2023-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $114.89 | 2024-2025 | Lupkynis |
| Medtronic, INC. | $82.99 | 2024-2025 | Minimed 780g |
| Pfizer INC. | $52.24 | 2024 | |
| Radius Health, INC. | $51.67 | 2024-2025 | Tymlos |
| Genzyme Corporation | $50.15 | 2025 | |
| Zimmer Biomet Holdings, INC. | $37.44 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Octapharma USA, INC. | $35.51 | 2025 | Octagam Immune Globulin (Human) |
| Xeris Pharmaceuticals, INC. | $35.49 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Glaxosmithkline, LLC. | $33.38 | 2023-2024 | Trelegy Ellipta |
| Organon LLC | $32.52 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $31.41 | 2023-2024 | Acthar |
| Sobi, INC | $28.81 | 2024-2025 | |
| Soleno Therapeutics, INC. | $22.91 | 2025 | Vykat Xr |
| Ardelyx, INC. | $20.51 | 2024 | Ibsrela |
| Corcept Therapeutics | $17.11 | 2025 | Korlym |
| Kyowa Kirin, INC. | $16.53 | 2024 | Crysvita |
| Ani Pharmaceuticals, INC. | $16.08 | 2024 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $16.07 | 2024 | Arcalyst |
| Invivyd INC | $15.71 | 2025 | Pemgarda |
| United Therapeutics Corporation | $14.59 | 2023 | Orenitram, Tyvaso |
| Tolmar, INC. | $14.11 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.98 | 2024 | Cyltezo |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Legunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.